Trial result ·
Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This study looked at people with severe aplastic anemia. They took part in a phase 3 trial of drugs that calm the immune system. In that trial, some people also got a drug called eltrombopag. Here, the team tested blood and bone marrow for gene changes. Tests were done at the start, at 6 months and at 24 months. The gene panels checked 31 genes, or 291 genes in a wider set.
What they found
The team got samples from 170 people at the start. There were 150 people at 6 months and 103 at 24 months. For 85 people, samples were tested at all 3 time points. Gene changes were more common at each later time point. On average, people had 0.4 changes at the start. This rose to 1.2 at 6 months and 2.5 at 24 months.
What it means for patients
The team says these gene changes in blood cells were common in aplastic anemia. They seemed more frequent after treatment than at the start. The team thinks this may show surviving stem cells growing in number. These may be cells that lived through damage caused by the immune system.
Why it is not certain yet
Not every person gave samples at every time point. Only 85 people were tested at all 3 times. The team words the rise with care, saying it only appeared higher. The abstract does not say if these changes harmed people. It also does not compare gene changes between the treatment groups. The idea about why the changes arise is a possible reason, not proven.
Source
Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag.
PubMed · PMID 42047558We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Aplastic anaemia publications